Bilateral cornea melting may be linked to AstraZeneca COVID-19 vaccine

Article

A 48-year-old male patient presented to an ophthalmic emergency department with what was described as progressive bilateral corneal melting 5 weeks after he received the first dose of a COVID-19 vaccine.

Bilateral cornea melting may be linked to AstraZeneca COVID-19 vaccine

Physicians in New Delhi reported a rare case of bilateral immune-mediated keratolysis (corneal melting) after administration of one dose of the ChAdOx1 nCoV-19 (Covishield, AstraZeneca) vaccination.1

This case may demonstrate a temporal association between this severe ocular adverse event after one dose of any of the available SARS-CoV-19 vaccines, according to first author Dr Tanveer Alam Khan and colleagues from the Cornea, Cataract and Refractive Surgery Services, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.

The patient was a 48-year-old man who presented to the ophthalmic emergency department with what was described as progressive bilateral corneal melting 5 weeks after he received the first dose of the COVID-19 vaccine.

The patient reported having experienced fever, diarrhea and vomiting during the first 2 weeks following the vaccination, which then subsided before the ocular symptoms began 3 weeks after he received the vaccination.

Ocular examination showed a visual acuity of light perception bilaterally with features of bilateral corneal melting with choroidal detachment on ultrasonography. Culturing was negative for microorganisms.

The patient underwent tectonic penetrating keratoplasty and the host corneal tissue was sent for analysis that included histopathology; bacterial and fungal cultures; polymerase chain reaction for herpes simplex virus; varicella zoster virus; cytomegalovirus; adenovirus; and SARS-CoV-2.

“Microbial culture was sterile and viral polymerase chain reaction reports were negative. Histopathological examination revealed dense inflammatory cell infiltration,” the investigators wrote.

According to the investigators, a detailed systemic workup revealed no underlying systemic or autoimmune pathology.

“Immune-mediated keratolysis after the ChAdOx1 nCoV-19 (Covishield) vaccination is a rare entity, and we believe that this is the first report of a temporal association between a serious ocular adverse event after a single dose of any SARS-CoV-19 vaccine,” they concluded. “It may be included as a possible adverse event associated with this vaccine.”

---

Reference
1. Khan TA, Navneet S, Livia K, et al. Bilateral immune-mediated keratolysis after immunization with SARS-CoV-2 recombinant viral vector vaccine. Cornea. P P 4 September 2021. DOIi:10.1097/ICO.0000000000002844.

Related Content:

Telemedicine ushers in new chapter in eye care

Managing retinal disorders: Lessons learned from COVID-19 (video)

Navigating COVID-19 with ophthalmic patients in the hospital setting

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.